Luoxin Pharmaceutical (002793.SZ) net loss to mother in 2024 was 962 million yuan

Zhitongcaijing · 04/14 11:33

According to the Zhitong Finance App, Luoxin Pharmaceutical (002793.SZ) released its 2024 annual performance report. During the reporting period, the company achieved operating income of 2,647 billion yuan, an increase of 11.99% over the same period last year; net profit attributable to shareholders of listed companies was -962 million yuan. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was -771 million yuan.